Stock Screener App

Gratuito -

Installare

7.06

3.22% -0.20

Gyre Therapeutics Inc (GYRE)

Panoramica Notizia Cronologia dei prezzi Perché GYRE Giù? Forum Previsione

Gyre Therapeutics Inc Borsa (GYRE) Ultime notizie

GYREGyre Therapeutics Inc Options - Finviz

Form 4 Gyre Therapeutics Inc For: 30 June By Investing.com - Investing.com Nigeria

Gyre Therapeutics (GYRE) director awarded 40,000 stock options at $5.95 - Stock Titan

GYRE (GYRE) director receives stock options for 40,000 common shares - Stock Titan

GYRE SEC FilingsGyre Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

US High Growth Tech Stocks to Watch - simplywall.st

Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Value Benchmark - marketscreener.com

GYRE THERAPEUTICS (GYRE): Kaskela Law LLC Announces Shareholder Investigation of Gyre Therapeutics and Encourages Long-Term GYRE Investors to Contact the Firm - ACCESS Newswire

Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Value-Defensive Index - marketscreener.com

Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Growth-Defensive Index - marketscreener.com

Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Defensive Index - marketscreener.com

Price to earnings forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView

Price to earnings forward of Gyre Therapeutics Inc – LS:A3EE5F - TradingView

Price to book forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView

Enterprise value to EBITDA forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView

Enterprise value to EBIT forward of Gyre Therapeutics Inc – TRADEGATE:L9S - TradingView

Price to earnings forward of Gyre Therapeutics Inc – TRADEGATE:L9S - TradingView

Gyre Therapeutics Inc (GYRE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Gyre Therapeutics Inc Actuals & Estimates (NASDAQ:GYRE) - TradingView

Enterprise value to revenue forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView

Price to book forward of Gyre Therapeutics Inc – LS:A3EE5F - TradingView

GYRE Forecast — Price Target — Prediction for 2027 - TradingView

Enterprise value to EBIT forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView

Price to sales forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView

Price to sales forward of Gyre Therapeutics Inc – LS:A3EE5F - TradingView

GNI’s Gyre Therapeutics files Form S-3 tied to Cullgen acquisition - TipRanks

Gyre Therapeutics | S-3: Registration statement for specified transactions by certain issuers - Moomoo

Form S-3 Gyre Therapeutics Inc For: 23 June By Investing.com - Investing.com Australia

Gyre Therapeutics (NASDAQ: GYRE) registers 30.2M resale shares post-merger - Stock Titan

Gyre Therapeutics (GYRE) COO trades 11,000 shares, retains 700,000 - Stock Titan

Gyre Therapeutics StockLong-term business model and pipeline focus - AD HOC NEWS

Gyre Therapeutics Inc (GYRE) Valuation: PE, PB & Fair Value Analysis - TradingKey

Gyre Therapeutics Inc (GYRE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Gyre Therapeutics Inc (GYRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Gyre Therapeutics Inc (GYRE) Institutional Confidence - TradingKey

Gyre Therapeutics Inc (GYRE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Gyre Therapeutics Inc (GYRE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Gyre Therapeutics Inc (GYRE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Gyre Therapeutics Inc (GYRE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Gyre Therapeutics Shareholders Approve Directors and Governance Measures - The Globe and Mail

Gyre Therapeutics stockholders approve all proposals at annual meeting By Investing.com - Investing.com Nigeria

Gyre Therapeutics stockholders approve all proposals at annual meeting - Investing.com

Gyre Therapeutics (NASDAQ: GYRE) investors back directors, pay and Series B conversion - Stock Titan

Gyre Therapeutics, Inc. Files 8-K with SEC: Company Information, Address, and NASDAQ Ticker GYRE - Minichart

Gyre COO Ye Weiguo sells $17,276 in company stock By Investing.com - Investing.com Canada

Gyre COO Ye Weiguo sells $17,276 in company stock - Investing.com

Gyre Therapeutics (GYRE) COO sells 2,800 shares after exercising options - Stock Titan

ZVRA Stock Price and Chart — NASDAQ:ZVRA - TradingView

GYRE Q1 2026 Earnings: EPS Surprises to the Upside, Revenue Not Reported, Stock SlipsForward EPS Estimate - newsline.com

Gyre Therapeutics, Inc. (GYRE) reports Q1 loss, lags revenue estimates - MSN

Gyre Therapeutics COO Ye Weiguo sells $128,885 in stock - Investing.com UK

Gyre Therapeutics COO Ye Weiguo sells $128,885 in stock By Investing.com - Investing.com South Africa

Gyre Therapeutics (GYRE) COO sells 20,918 shares after exercising options - Stock Titan

[Form 4] GYRE THERAPEUTICS, INC. Insider Trading Activity - Stock Titan

CEO of Gyre Therapeutics (NASDAQ: GYRE) receives 120,000 stock options - Stock Titan

INSM

$113.68

1.95%

RPRX

$57.69

1.46%

ROIV

$36.11

1.96%

MRNA

$79.68

2.70%

ONC

$307.27

0.65%

RVMD

$190.47

0.31%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters